ASX:RNO Rhinomed (RNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Rhinomed Stock (ASX:RNO) 30 days 90 days 365 days Advanced Chart Get Rhinomed alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume452,773 shsAverage VolumeN/AMarket CapitalizationA$11.47 millionP/E RatioN/ADividend Yield3.01%Price TargetN/AConsensus RatingN/A Company Overview Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia. Read More Receive RNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhinomed and its competitors with MarketBeat's FREE daily newsletter. Email Address RNO Stock News HeadlinesShareholders Will Probably Hold Off On Increasing Rhinomed Limited's (ASX:RNO) CEO Compensation For The Time BeingNovember 10, 2023 | finance.yahoo.comInsider Buyers Lose AU$435k As Rhinomed Sheds AU$1.4mOctober 30, 2023 | finance.yahoo.comPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.July 4 at 2:00 AM | Paradigm Press (Ad)Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in AustraliaOctober 12, 2023 | msn.comMeredith George Bought 6.7% More Shares In Rhinomed \May 23, 2023 | finance.yahoo.comMeredith George Just Bought 8.2% More Shares In Rhinomed Limited (ASX:RNO)April 1, 2023 | finance.yahoo.comRhinomed First Half 2023 Earnings: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)March 3, 2023 | finance.yahoo.comRhinomed Limited (ASX:RNO) insiders placed bullish bets worth AU$2.2m in the last 12 monthsDecember 30, 2022 | finance.yahoo.comSee More Headlines RNO Stock Analysis - Frequently Asked Questions How were Rhinomed's earnings last quarter? Rhinomed Limited (ASX:RNO) announced its quarterly earnings results on Thursday, February, 28th. The company reported ($0.02) earnings per share for the quarter. Rhinomed had a positive trailing twelve-month return on equity of 1,591.14% and a negative net margin of 145.98%. What other stocks do shareholders of Rhinomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhinomed investors own include Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Lowe's Companies (LOW), Energy Vault (NRGV) and Medicine Man Technologies (SHWZ). Company Calendar Last Earnings2/28/2019Today7/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:RNO CIKN/A Webwww.rhinomed.com.au Phone+61-3-84160900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$10.91 million Net Margins-145.98% Pretax MarginN/A Return on Equity1,591.14% Return on Assets-101.64% Debt Debt-to-Equity Ratio-93.28 Current Ratio0.27 Quick Ratio1.28 Sales & Book Value Annual SalesA$8.05 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.48 Book ValueA($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares286,780,000Free FloatN/AMarket CapA$11.47 million OptionableNot Optionable Beta0.88 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (ASX:RNO) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhinomed Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhinomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.